Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Brigitte Brieschke, Garrett L. Robinson, Sangeetha Rajagopalan, Hilario J. Ramos, Jensing Liu, Jack P. Higgins and Erin K. Willert
Title Targeted Engineered Toxin Bodies provide a novel mechanism of action against HER2 positive cancers
Journal Cancer Res
Abstract Text Cancer Res 2018;78(13 Suppl):Abstract nr 5769


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
MT-5111 MT-5111 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
MT-5111 MT5111|MT 5111 HER2 (ERBB2) Antibody 47 MT-5111 is an Erbb2 (Her2) antibody in conjugation with a ribosome-targeting toxin, which may demonstrate cytotoxicity against Erbb2 (Her2)-positive tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 5769).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive Advanced Solid Tumor predicted - sensitive MT-5111 Preclinical - Cell culture Actionable In a preclinical study, MT-5111 demonstrated toxicity against Erbb2 (Her2) positive tumor cell lines in culture regardless of their sensitivity to Kadcyla (ado-trastuzumab emtansine) (Cancer Res 2018;78(13 Suppl):Abstract nr 5769). detail...